Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
The purpose of this study is to evaluate the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability following single oral doses of 0.001 mg to 2.5 mg dapagliflozin in healthy subjects.
Epistemonikos ID: c1c4bbbe74a63c4dec5c4c5866a3acdf6fafae81
First added on: May 05, 2024